News & Updates

In a real-world study presented at IDWeek 2023, dalbavancin has been shown to be an effective treatment alternative for patients with invasive gram-positive infections.

Treatment with single or multiple doses of ceftazidime-avibactam (CAZ-AVI) results in favourable clinical outcomes and is well tolerated in hospitalized neonates and young infants with suspected or confirmed bacterial infections, according to a phase IIa study presented at IDWeek 2023.

Bivalent COVID-19 vaccine conferred protection against SARS-COV-2 infection among children and adolescents aged 5–11 years, according to a recent study presented at IDWeek 2023.

The use of chikungunya virus-like particle vaccine (CHIKV VLP) results in significantly higher seroresponse rate* and superior immunogenicity in adolescents and adults compared with placebo, according to two pivotal phase III trials presented at IDWeek 2023.

In a real-world cohort, virologically suppressed HIV patients who switched from a prior regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) were less likely to discontinue their regimen than those who switched to dolutegravir/lamivudine (DTG/3TC).

The respiratory syncytial virus (RSV) vaccine by GSK demonstrated sustained effectiveness of about 67 percent among adults 60 years or older across two full RSV seasons in a phase III study, says an infectious disease expert who reported findings at IDWeek 2023.